SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Bristol Myers Squibb Presents First Phase 3 Data on KarXT

Bristol Myers Squibb presented first clinical data from two Phase 3 studies in the ADEPT program evaluating KarXT for psychosis associated with Alzheimer’s disease.

BMY

Related stories